重组p53基因联合介入治疗晚期肝癌疗效分析

Analysis of clinical effect of advanced liver cancer in interventional therapy using reorganization p53 gene

目的检测重组p53基因的临床治疗效果。方法利用流式细胞术和体内淋巴细胞微核实验方法分别检测患者的突变型p53基因表达情况和自发体内微核形成率;用Karuafsk方法对治疗效果进行评价。结果经过2个疗程治疗,患者腹胀等症状明显好转,生存期生活质量显著改善,C组的Karuafsky明显提高,其中肝功能状态C组好转10例,T组21例,生活质量提升情况,C组中有17例,T组中有24例,C组中生存满意者,差异有统计学意义(P<0.05)。介入治疗后,p53平均表达率显著下降。经过介入治疗2个疗程后,无论与自然人群还是和C组相比,患者的Karuafsk评价值显著升高,p53平均表达率和平均MNF值均显著下降。结论重组人p53腺病毒注射液结合肝动脉介入疗法治疗肝癌患者安全有效,能较好地控制肿瘤的进一步发展,值得在临床上推广使用。

Objective To analyze the effect of reorganization of P53 gene. Methods Spontaneous mutant type p53 gene expression in patients was detected using flow cytometry; The therapeutic effect was evaluated by Karuafsk method. Re- suits After two courses of treatment, symptoms such as abdominal distention was improved markedly, and the survival quality of life was improved significantly. After interventional treatment, the average expression rate of p53 was reducted significantly. After interventional treatment, Karuafsk rised significantly, and average p53 expression rate and average MNF values have dropped significantly. Conclusion Human recombinant p53 adenovirus injection combined with hepatic artery interventional therapy is effective and security for patients of HCC,it also can control the further development of tumor well, therefore, it is worth popularizing in clinical use.